Enlivex Therapeutics Ltd. has released its unaudited financial results for the first quarter ending March 31, 2025. The company reported no revenue for the period, consistent with the same quarter in 2024. The net loss for the quarter was $3.452 million, an improvement from a net loss of $4.140 million in the same period last year. Research and development expenses decreased to $2.550 million from $2.857 million, and general and administrative expenses fell to $954,000 from $1.093 million in the previous year. Enlivex's management and board of directors remain optimistic about the company's financial resources, stating they are sufficient to continue product development for at least the next twelve months. However, the company may seek additional capital within this period. The long-term operational viability of Enlivex is dependent on further financial support and the successful development and revenue generation from its product candidates.